In addition to PSA recurrence, which is the first indication of prostate cancer progression, we next determined if the protein levels of YB-1 and MTA1 correlate with clinically relevant end points beyond changes in the PSA level including future need for androgen deprivation therapy or radiation therapy. This evidence concerns the gene MTA1 and prostate cancer.